545. A Retrospective Review of 30-day Mortalities in Solid-Organ Transplant Recipients (SOT) versus Non-Transplant Patients (NTP) Receiving Remdesivir (REM) and Dexamethasone (DEX) for COVID-19 Pneumonia

BACKGROUND: Treating COVID-19 infection in SOT is challenging due to long-term use of immunosuppressive agents. REM is the only FDA-approved anti-viral for SARS-COV-2 infection. DEX showed decrease in mortality in the Recovery Trial. COVID-19 treatment guidelines for SOT patients are the same as NTP...

Descripción completa

Detalles Bibliográficos
Autores principales: Vyas, Krina, Epps, Kevin L, Zhang, Nan, Shah, Sadia, Soto-Arenall, Matthew, Brumble, Lisa, Libertin, Claudia R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644915/
http://dx.doi.org/10.1093/ofid/ofab466.744

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644915/
http://dx.doi.org/10.1093/ofid/ofab466.744

Ejemplares similares